Zollinger-Ellison syndrome classification: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
*The World Health Organization classifies NETs into two broad categories, well differentiated and poorly differentiated, and most gastrinomas are considered well-differentiated NETs on the basis of histopathological analysis.
*The World Health Organization classifies [[neuroendocrine tumors]] (NETs) into two broad categories, well differentiated and poorly differentiated, and most [[Gastrinoma|gastrinomas]] are considered well-differentiated [[neuroendocrine tumors]] (NETs) on the basis of [[histopathological]] analysis.


==Classiffication==
==Classiffication==
*Gastrinomas are derived from the [[enteroendocrine cells]] that arise from the embryologic endoderm, and form tumors mainly in the pancreas, but also in the proximal small intestine. Because of their origin, these are generally classified under the larger umbrella term of [[neuroendocrine tumors]] (NETs). <ref name="pmid7904550">{{cite journal |vauthors=Norton JA |title=Neuroendocrine tumors of the pancreas and duodenum |journal=Curr Probl Surg |volume=31 |issue=2 |pages=77–156 |year=1994 |pmid=7904550 |doi= |url=}}</ref>
*Gastrinomas are derived from the [[enteroendocrine cells]] that arise from the [[embryologic]] [[endoderm]], and form tumors mainly in the [[pancreas]], but also in the proximal [[small intestine]]. Because of their origin, these are generally classified under the larger umbrella term of [[neuroendocrine tumors]] (NETs). <ref name="pmid7904550">{{cite journal |vauthors=Norton JA |title=Neuroendocrine tumors of the pancreas and duodenum |journal=Curr Probl Surg |volume=31 |issue=2 |pages=77–156 |year=1994 |pmid=7904550 |doi= |url=}}</ref>
*The World Health Organization classifies NETs into two broad categories, well differentiated and poorly differentiated, and most gastrinomas are considered well-differentiated NETs on the basis of histopathological analysis. It has been observed that most gastrinomas arise in the duodenum, with tumors located in the pancreas carrying greater malignant potential. <ref name="pmid23582915">{{cite journal| author=O'Toole D, Delle Fave G, Jensen RT| title=Gastric and duodenal neuroendocrine tumours. | journal=Best Pract Res Clin Gastroenterol | year= 2012 | volume= 26 | issue= 6 | pages= 719-35 | pmid=23582915 | doi=10.1016/j.bpg.2013.01.002 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23582915  }} </ref>
*The World Health Organization classifies [[neuroendocrine tumors]] (NETs) into two broad categories, well differentiated and poorly differentiated, and most [[Gastrinoma|gastrinomas]] are considered well-differentiated [[neuroendocrine tumors]] (NETs) on the basis of histopathological analysis. It has been observed that most [[Gastrinoma|gastrinomas]] arise in the duodenum, with tumors located in the [[pancreas]] carrying greater [[malignant]] potential. <ref name="pmid23582915">{{cite journal| author=O'Toole D, Delle Fave G, Jensen RT| title=Gastric and duodenal neuroendocrine tumours. | journal=Best Pract Res Clin Gastroenterol | year= 2012 | volume= 26 | issue= 6 | pages= 719-35 | pmid=23582915 | doi=10.1016/j.bpg.2013.01.002 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23582915  }} </ref>


==References==
==References==

Revision as of 17:00, 1 August 2017

Zollinger-Ellison syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Zollinger-Ellison syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Zollinger-Ellison syndrome classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Zollinger-Ellison syndrome classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Zollinger-Ellison syndrome classification

CDC on Zollinger-Ellison syndrome classification

Zollinger-Ellison syndrome classification in the news

Blogs on Zollinger-Ellison syndrome classification

Directions to Hospitals Treating Zollinger-Ellison syndrome

Risk calculators and risk factors for Zollinger-Ellison syndrome classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aravind Reddy Kothagadi M.B.B.S[2]

Overview

Classiffication

References

  1. Norton JA (1994). "Neuroendocrine tumors of the pancreas and duodenum". Curr Probl Surg. 31 (2): 77–156. PMID 7904550.
  2. O'Toole D, Delle Fave G, Jensen RT (2012). "Gastric and duodenal neuroendocrine tumours". Best Pract Res Clin Gastroenterol. 26 (6): 719–35. doi:10.1016/j.bpg.2013.01.002. PMID 23582915.

Template:WH Template:WS